ENTX Latest Press Releases

-- October 27, 2026 --

Entera Appoints Global Research and Development Leader Dr. Juan Camilo Arjona Ferreira to Its Board of Directors Globe Newswire 8:00 AM

-- October 13, 2026 --

Entera Presents Markedly Enhanced Anabolic Effects of EB613 (First-in-Class Oral PTH(1-34) Tablet) in Postmenopausal Women with Osteoporosis at High Risk of Fracture and Showcases Phase 3 Design at ASBMR 2026 Annual Meeting Globe Newswire 7:00 AM

-- October 8, 2026 --

Entera Bio Announces Additional Presentation of EB613 Phase 3 Study Design at the ASBMR 2026 Annual Meeting Globe Newswire 8:00 AM

-- October 6, 2026 --

Entera Appoints Global BioPharma Executive Laura Hamill to Its Board of Directors, Expanding Commercial Expertise Globe Newswire 8:00 AM

-- August 27, 2026 --

Correction: Entera to Participate in Upcoming Fall Investor Conferences Globe Newswire 9:44 AM

Entera to Participate in Upcoming Fall Investor Conferences Globe Newswire 8:00 AM

-- August 18, 2026 --

Entera Appoints Global Pharmaceutical Leader Riccardo Paolo Camisasca, M.D., as Chief Medical Officer Ahead of Planned EB613 Phase 3 Initiation Globe Newswire 8:00 AM

-- August 7, 2026 --

Entera Announces Second Quarter 2026 Financial Results and Business Updates Globe Newswire 4:05 PM

-- August 4, 2026 --

Entera Bio Phase 2 Data Supporting EB613's (Oral PTH(1-34)) Anabolic Effect on Postmenopausal Women with Osteoporosis at High Risk for Fracture Selected for Plenary Poster Session Presentation at the ASBMR 2026 Annual Meeting Globe Newswire 8:30 AM

-- July 31, 2026 --

Entera Bio to Participate in the Canaccord Genuity 46th Annual Growth Conference Globe Newswire 4:30 PM

-- July 29, 2026 --

Greenberg Traurig Advises Entera Bio in Record $275M Israeli Biotech PIPE PRNewswire 3:00 PM

-- July 27, 2026 --

Entera Bio Announces Pricing of Oversubscribed $275 Million Private Placement Globe Newswire 8:30 AM

-- June 23, 2026 --

Positive FDA Feedback on Phase 3 Brings Entera Bio's Oral Osteoporosis Pill One Step Closer to Market Globe Newswire 8:50 AM

-- June 22, 2026 --

Entera Bio Receives Positive FDA Feedback on 12-Month Registrational Phase 3 Study for EB613 - the First Oral Anabolic Tablet in Development for Postmenopausal Women with Osteoporosis Globe Newswire 8:30 AM

-- June 16, 2026 --

Entera Reports Robust Preclinical Data for EB612 (Oral LA-PTH(1-34)) for Hypoparathyroidism and EB618 (Oral GLP-1/Glucagon) for Obesity at ENDO 2026 Globe Newswire 8:33 AM

-- June 15, 2026 --

ENDO 2026 Oral Presentation Highlights Comparative Clinical Data for Entera's Breakthrough Single Tablet EB613 (First-in-Class Oral PTH(1-34) Anabolic for Osteoporosis) Globe Newswire 8:45 AM

Market Data Delayed 15 Minutes